MedTrace Logo

Investigation of GLP-2 Mechanism of Action (GA-8)

NCT03159741 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-01-18

No results posted yet for this study

Summary

Glucagon-like peptide-2 (GLP-2) is a naturally occuring hormone secreted to the circulation in response to food ingestion. Previous studies have shown that GLP-2 and incretins inhibit the bone resorption. However, the mechanism is unknown. In the present study we will investigate the mechanism of action using a receptor specific inhibitor.

Conditions

  • Healthy

Interventions

OTHER

Inhibitor + GLP-2

Inhibitor and GLP-2 are used as study tools.

OTHER

Placebo + GLP-2

Placebo and GLP-2 are used as study tools.

OTHER

Placebo + GIP

Placebo and GIP are used as study tools.

OTHER

Placebo + Saline

Placebo

Sponsors & Collaborators

  • Hvidovre University Hospital

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Mette Rosenkilde, MD · University of Copenhagen

  • Sten Madsbad, MD · Hvidovre University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-16
Primary Completion
2017-09-29
Completion
2017-09-29

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03159741 on ClinicalTrials.gov